Adaptimmune
Oxford
About Adaptimmune
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $499.5M
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2024)
- Ticker: nasdaq:ADAP
- Website: adaptimmune.com
- Phone: +1 (215) 825 9260
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/adaptimmune-62818 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.